Clinuvel Pharmaceuticals Limited · ASX:CUV
Clinuvel Pharmaceuticals — FY2024 Earnings Presentation
13 slides from Clinuvel Pharmaceuticals's earnings presentation, Aug 29, 2024
Slide 1: Financial Year Ended 30 June 2024 Investor Briefing
For personal use only Financial Year Ended 30 June 2024 Investor Briefing : 29 August 2024 Peter Vaughan Chief Financial Officer | Malcolm Bull Head of Australia Operations & Investor Relations ASX: CUV | Börse Frankfurt: UR9 | ADR Level 1: CLVLY
Slide 2: Forward-looking statement
Forward-looking statement CLINUVEL GROUP For personal use only This release contains forward-looking statements, which reflect the current beliefs and expectations of CLINUVEL’s management. Statements may involve a number of known and unknown risks that could cause our future results, performance, o
Slide 3: FY2024: Strong Financial Results
FY2024: Strong Financial Results For personal use only Consolidated Entity 30 June 2024 Change • Increase in revenues, net profit, cash Total Revenues, Interest and Other Income, $m 95.306 up 15% - growth EPP market EU & US Total Expenses, $m 44.627 up 19% - controlled fixed costs Net Profit Before
Slide 4: Expansion Strategy
Expansion Strategy Since FY2021, diversification for long-term sustainability For personal use only Integration of key functions ‘in-house’ Distribution Melanocortin product Technology translation SCENESSE® development, clinical studies to PhotoCosmetic products Focus on increasing, SCENESSE ®, PRÉN
Slide 5: Long-term Profitability
Long-term Profitability For personal use only • 8 years consecutive annual growth June Year, A$m in revenues (CAGR 38%) 100 60 80 50 • Controlling fixed costs supports 60 expansion initiatives (CAGR 20%) 40 40 • YoY growth EBIT, NPAT 20 30 0 20 • Debt to Equity Ratio: 14% -20 -40 10 • Return on Equi
Slide 6: Analyses of Expenses FY22-23-24
Analyses of Expenses FY22-23-24 For personal use only • total increase OPEX 19% Key Expenses Categories, A$m • personnel-related Personnel-related increase integrating key functions in-house Materials and related expenses • materials and related Non-cash expenses expenses offset by changes in invent
Slide 7: Expenses Plan
Expenses Plan 5-Years to 30 June 2025 (A$175.0m forecast) For personal use only 200 • controlled increase in expenses to support growth 175 • 4 years cumulative expenses, 150 excluding CBM expenses, 125 = 72% of five-year plan achieved = A$125.2 m spent to 30 June ‘24 100 75 • new 3-year expenses pl
Slide 8: Strong Balance Sheet
Strong Balance Sheet For personal use only Assets & Liabilities, A$m On 30 June 2023 2024 Cash Reserves, A$m 240 200 Total Assets $193.7m $231.1m (+19%) 180 200 Total Liabilities $29.1m $28.1m (-3%) 160 • trade creditors, suppliers 160 140 • debt-free 120 120 100 Cash Reserves $156.8m $183.9m (+17%)
Slide 9: Clinical Pipeline: skin and brain
Clinical Pipeline: skin and brain Melanocortin based pharmaceuticals for unmet needs For personal use only Preclinical Phase I Phase II Phase III Commercial SCENESSE® (afamelanotide 16 mg) in adult EPP (EEA, UK, CH, USA, ISL, CAN, AUS) SCENESSE® (afamelanotide 16 mg) in adolescent EPP SCENESSE® (afa
Slide 10: Catalysts
Catalysts For personal use only 2024 SCENESSE® adolescent use – EMA outcome | adolescent PK study CUV052 – start | regulatory filing Canada ●●● CUV105, n=200 ASX 21 Aug ’24: extended recruitment, relaxation inclusion criteria Vitiligo CUV107, start n=200 ●●● XP – DNA Repair CUV151-156 readouts | CUV
Slide 11: Looking Forward: 2025 and Beyond
Looking Forward: 2025 and Beyond Building a melanocortin house For personal use only A pharmaceutical group, diversified- integrated to sustain long-term performance Products for multiple indications and healthcare solutions • 3 pharmaceutical products • 8 conditions treated Porphyria XP Stroke • 3
Slide 12: Discussion
For personal use only DISCUSSION
Slide 13: Authorised for ASX release; investor contact details
For personal use only Authorised for ASX release by the Board of Directors of CLINUVEL PHARMACEUTICALS LTD Head of Investor Relations: Mr Malcolm Bull, CLINUVEL PHARMACEUTICALS LTD Investor Enquiries: https://www.clinuvel.com/investors/contact-us Level 22, 535 Bourke Street, Melbourne – Victoria, Au
Clinuvel Pharmaceuticals — FY2024 Earnings Presentation on 6ix